Ligand Pharmaceuticals (LGND) Enterprise Value (2010 - 2026)
Ligand Pharmaceuticals (LGND) reported Enterprise Value of -$779.4 million for Q1 2026, down 273.1% on a YoY basis from $450.3 million in Q1 2025, and down 6.26% sequentially from -$733.5 million in Q4 2025.
Ligand Pharmaceuticals (LGND) Enterprise Value (2010 - 2026) Analysis & Trends
Ligand Pharmaceuticals (LGND) has 17 years of Enterprise Value data on file, last reported at -$779.4 million in Q1 2026.
- For the quarter ending Q1 2026, Enterprise Value fell 273.1% year-over-year to -$779.4 million; the trailing twelve-month figure through Mar 2026 stood at -$779.4 million (down 273.1% YoY), and the FY2025 full-year result was -$733.5 million, down 186.35% from the prior year.
- Enterprise Value fell to -$779.4 million in Q1 2026, from -$733.5 million in the prior quarter.
- In the past five years, Enterprise Value ranged from a high of -$38.3 million in Q2 2024 to a low of -$779.4 million in Q1 2026.
- A 5-year average of -$285.8 million and a median of -$211.9 million in 2022 frame the typical range for Enterprise Value.
- Across the five-year window, Enterprise Value surged 82.52% in 2024 and tumbled 788.97% in 2025, its largest moves.
- Tracing LGND's Enterprise Value over 5 years: stood at -$211.9 million in 2022, then climbed by 19.62% to -$170.3 million in 2023, then tumbled by 50.41% to -$256.2 million in 2024, then slumped by 186.35% to -$733.5 million in 2025, then fell by 6.26% to -$779.4 million in 2026.
- Business Quant data shows LGND's Enterprise Value at -$779.4 million in Q1 2026, -$733.5 million in Q4 2025, and -$664.5 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Enterprise Value (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -283.54 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | -61.40 Mn |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | -4.79 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -32.26 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | -7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | -8.75 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | -5.18 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -1.91 Bn |
| 10 | Ligand Pharmaceuticals | 6.05 Bn | 5.27 Bn | 48.45 Mn | -779.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -779.41 Mn |
| Dec 31, 2025 | -733.52 Mn |
| Sep 30, 2025 | -664.52 Mn |
| Jun 30, 2025 | -245.02 Mn |
| Mar 31, 2025 | -208.90 Mn |
| Dec 31, 2024 | -256.17 Mn |
| Sep 30, 2024 | -74.75 Mn |
| Jun 30, 2024 | -38.28 Mn |
| Mar 31, 2024 | -310.59 Mn |
| Dec 31, 2023 | -170.31 Mn |
| Sep 30, 2023 | -190.50 Mn |
| Jun 30, 2023 | -219.04 Mn |
| Mar 31, 2023 | -282.67 Mn |
| Dec 31, 2022 | -211.87 Mn |
| Sep 30, 2022 | -121.41 Mn |
| Jun 30, 2022 | -147.94 Mn |
| Mar 31, 2022 | -204.00 Mn |
| Dec 31, 2021 | -341.11 Mn |
| Sep 30, 2021 | -323.21 Mn |
| Jun 30, 2021 | -301.84 Mn |